Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Broccoli Sprout Extracts in Healthy Volunteers: A Pilot Study of Nrf2 Pathway Modulation in Oral Mucosa (BSE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02023931
Recruitment Status : Completed
First Posted : December 30, 2013
Last Update Posted : November 13, 2017
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Julie E. Bauman, MD, MPH, University of Pittsburgh

Brief Summary:

A pilot study has been designed to determine (primary objective) if three brief interventions with three oral BSE regimens will alter mRNA biomarkers of Nrf2 pathway signaling, including NQO1, GSTs and AKRs, in the oral mucosa of healthy subjects. Quantitative distribution data and preliminary effect size for specific Nrf2 targets, as measured in serial buccal cell scrapings, will be determined during the course of 3-day exposures to three BSE regimens. These data will inform the design of a randomized, phase II chemoprevention trial in patients with HPV-negative HNSCC.

Ten healthy volunteers will be recruited for this pilot study, Age ≥ 18 years, both male and female: 1) The non-cancer population presenting to the University of Pittsburgh Eye and Ear Institute or the Hillman Cancer Center. This may include patients with benign disease or their friends/family members, or friends/family members of patients with cancer; 2) Professionals, staff, or students at the University of Pittsburgh.

Condition or disease Intervention/treatment Phase
Healthy Subject Drug: Broccoli Sprout Extract (BSE) Early Phase 1

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Broccoli Sprout Extracts in Healthy Volunteers: A Pilot Study of Nrf2 Pathway Modulation in Oral Mucosa
Study Start Date : March 2014
Actual Primary Completion Date : April 2014
Actual Study Completion Date : January 2015

Arm Intervention/treatment
Experimental: Broccoli Sprout Extract Drink
Three different regimens of BSE delivery will be evaluated in each participant, with participants serving as their own controls. Each regimen will involve a 3 day exposure, with daily collection of buccal cell scrapings. Between regimens, a minimum 3 day (72 hour) washout period will occur.
Drug: Broccoli Sprout Extract (BSE)
  1. The first regimen will involve oral delivery and ingestion of 600 μmole doses of glucoraphanin-rich BSE (GRR-BSE), and will represent systemic delivery of sulforaphane to oral mucosa, due to the necessity to metabolize GRR-BSE in the gut.
  2. The second regimen will involve oral delivery and ingestion of 100 μmole doses of sulforaphane-rich BSE (SFR-BSE), which will represent a combination of systemic and topical delivery to the oral mucosa.
  3. The third regimen will isolate topical exposure of the oral mucosa to sulforaphane. Participants will swish, hold, then spit 100 μmole doses of SFR-BSE. This regimen (SFR-BSE(T)) will theoretically isolate the pharmacodynamic impact of topical exposure of the oral mucosa to sulforaphane.
Other Names:
  • Glucoraphanin-rich BSE (GRR-BSE)
  • Sulforaphane-rich BSE (SFR-BSE)

Primary Outcome Measures :
  1. Determine the modulation of the Nrf2 pathway in response to short term exposure to three BSE regimens [ Time Frame: Three to 11 weeks ]

    The primary objective is limited to obtaining preliminary estimates of Nrf2 pathway modulation from buccal cell specimens samples all collected during each of the three 5 day intervention periods. Endpoints include mRNA transcript levels of certain genes or enzymes regulated by Nrf2.

    Note that the goals of this study are limited to obtaining initial pharmacodynamic estimates of Nrf2 pathway modulation for each BSE intervention. Accordingly, no hypothesis testing or comparative analyses are planned. The data collected in this pilot study may be used to plan a future definitive prevention trial.

Secondary Outcome Measures :
  1. Estimate modulation of Nrf2 pathway markers in PBMCs and metabolites of SFN in urine [ Time Frame: Three to 11 weeks ]
    Individual subjects profile plots will be constructed for each endpoint as measured at various times over days 1-5 of each regimen will be plotted. An omnibus test of change over time such as the Friedman test of Mack-Skillings test will be conducted to verify general endpoint modulation. Regimen-specific profiles will be estimated with mixed linear or generalized mixed linear models

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Age ≥ 18 years. Children will not be recruited into this study because children do not develop head and neck cancer.
  2. Both males and females are eligible.
  3. Members of all racial and ethnic groups are eligible.
  4. Smoking and non-smoking people are eligible. The tobacco use assessment form must be completed following consent and registration (Appendix B).
  5. No current or former diagnosis of cancer, with the exception of: excised and cured non-melanoma skin cancer; or carcinoma in situ of the cervix
  6. No use of chronic prescribed medications which are potent inducers or inhibitors of CYP3A4 (Appendix A)
  7. No chronic anticoagulation
  8. No chronic use of steroids
  9. Karnofsky Performance Scale ≥90% (Appendix C)
  10. Able to provide written, informed consent
  11. For women of child-bearing potential (WOCBP), a negative urine pregnancy test must be documented within 7 days prior to the first study intervention
  12. No history of food intolerance to broccoli or pineapple and lime juices
  13. Willing to avoid cruciferous vegetables during the study interventions (Appendix D)
  14. Willing to avoid grapefruit or grapefruit juice 48 hours prior to or during the study
  15. Willing to avoid daily vitamins and anti-inflammatory medications prior to and during the study
  16. Potential effects of Broccoli sprout extract on the developing human fetus: The effects of Broccoli Sprout Extract on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and for the duration of study participation

Exclusion Criteria:

Failure to meet the above criteria

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02023931

Layout table for location information
United States, Pennsylvania
Eye and Ear Institute
Pittsburgh, Pennsylvania, United States, 15213
UPMC Hillman Cancer Center (University of Pittsburgh Cancer Institute)
Pittsburgh, Pennsylvania, United States, 15232
Sponsors and Collaborators
Julie E. Bauman, MD, MPH
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Julie E Bauman, MD University ofPittsburgh
Layout table for additonal information
Responsible Party: Julie E. Bauman, MD, MPH, Assistant Professor of Medicine,Director of the Section of Head and Neck Cancer, University of Pittsburgh Identifier: NCT02023931    
Other Study ID Numbers: 13-079
5P50CA097190-09 ( U.S. NIH Grant/Contract )
First Posted: December 30, 2013    Key Record Dates
Last Update Posted: November 13, 2017
Last Verified: November 2017
Keywords provided by Julie E. Bauman, MD, MPH, University of Pittsburgh:
Oral mucosa
Nrf2 pathway
Broccoli Sprout Extract
Head and Neck Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Anticarcinogenic Agents
Protective Agents
Physiological Effects of Drugs
Antineoplastic Agents